In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an alternative to the ...
In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other best pharma stocks to buy according to hedge funds. The US pharmaceutical sector is ...
In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase “defensive” as ...
In recent trading, shares of Amgen Inc (Symbol: AMGN) have crossed above the average analyst 12-month target price of $317.58, changing hands for $317.82/share. When a stock reaches the target an ...
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The company’s shares closed last Friday at $324.86.
Amgen’s dividend payout ratio is currently 126.09%. Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to ...
In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best performing Dow ...
Just today, Amgen (AMGN) announced updated Uplizna results showing a deepening of responses six months after a single repeat infusion, Opco points out. It believes extrapolating from Cartesian’s ...
Deep-pocketed investors have adopted a bullish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...
Amgen (NASDAQ:AMGN) shares snapped six straight sessions of gains, as the stock ended 3% lower at $306.2 on Wednesday. The biotechnology company gained 7.8% in the preceding six sessions. The ...
Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...